Lee Willis C's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Sep 2, 2026
- Accession no.
- 0001193125-26-380023
- Filed
- Sep 2, 2026, 3:05 PM ET
- Trade date
- May 30, 2025-Aug 31, 2026
- Filing delay
- 460 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market purchases total $18.1K. It was filed 460 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Willis CCIK 0001517775 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 30, 2025 | Common stock, $0.001 par value | PPurchaseAcquired | +70,000 | $0.02F1 | +$1,400 | 229,400 | Indirect | |
| Aug 29, 2025 | Common stock, $0.001 par value | PPurchaseAcquired | +170,000 | $0.01F2 | +$1,700 | 275,400 | Indirect | |
| Aug 25, 2026 | Common stock, $0.001 par value | PPurchaseAcquired | +46,000 | $0.04F3 | +$1,840 | 445,400 | Indirect | |
| Aug 27, 2026 | Common stock, $0.001 par value | PPurchaseAcquired | +50,000 | $0.05F4 | +$2,500 | 495,400 | Indirect | |
| Aug 28, 2026 | Common stock, $0.001 par value | PPurchaseAcquired | +94,767 | $0.06F5 | +$5,686.02 | 590,167 | Indirect | |
| Aug 31, 2026 | Common stock, $0.001 par value | PPurchaseAcquired | +100,000 | $0.05F6 | +$5,000 | 690,167 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.01 to $0.02, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1), footnote (2), footnote (3), footnote (4), footnote (5) and footnote (6).
Referenced by the price of 1 transaction in Table I.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0109 to $0.011, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.034 to $0.039, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.044 to $0.051, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.050 to $0.075, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.046 to $0.05, inclusive.
Referenced by the price of 1 transaction in Table I.